MedTrace Logo

Plasmapheresis Before Rituximab in Cryoglobulinemia

NCT04692363 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2020-12-31

No results posted yet for this study

Summary

Initial worsening following initiation of rituximab therapy in patients with cryoglobulinemic vasculitis was described in 3.6% of cases. This worsening is often a serious condition, with high levels of mortality.

The objective of our study is to evaluate the efficacy of preventive plasmapheresis prior to the introduction of rituximab performed in Montpellier France since 2013 by assessing the frequency and severity of this flare effect in these patients compared to those reported in the literature.

Conditions

  • Cryoglobulinemic Vasculitis

Sponsors & Collaborators

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • Charles HERBAUX, assistant Professor · University Hospital, Montpellier

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-01-01
Primary Completion
2021-12-01
Completion
2021-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04692363 on ClinicalTrials.gov